Forte Biosciences Inc.

40.58-0.2400-0.59%Vol 80.02K1Y Perf 106.87%
Jun 14th, 2021 16:00 DELAYED
BID40.00 ASK48.12
Open40.57 Previous Close40.82
Pre-Market- After-Market-
 - -  - -%
Target Price
86.00 
Analyst Rating
— — 0.00
Potential %
111.93 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap548.32M 
Earnings Rating
Price Range Ratio 52W %
67.00 
Earnings Date
10th May 2021

Today's Price Range

40.3841.81

52W Range

13.3553.99

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-4.13%
1 Month
28.38%
3 Months
41.34%
6 Months
11.73%
1 Year
106.87%
3 Years
-70.30%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FBRX40.58-0.2400-0.59
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.39-0.367.69
Q03 2020-0.32-0.46-43.75
Q02 2020--9.52-
Q01 2020--6.45-
Q04 2019-8.25-6.6020.00
Q03 2019-10.19-11.69-14.72
Q02 2019-11.24-10.794.00
Q01 2019-11.24-11.091.33
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.39
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume80.02K
Shares Outstanding13.51M
Trades Count1.47K
Dollar Volume3.48M
Avg. Volume163.20K
Avg. Weekly Volume97.71K
Avg. Monthly Volume114.08K
Avg. Quarterly Volume214.27K

Forte Biosciences Inc. (NASDAQ: FBRX) stock closed at 40.58 per share at the end of the most recent trading day (a -0.59% change compared to the prior day closing price) with a volume of 80.02K shares and market capitalization of 548.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9 people. Forte Biosciences Inc. CEO is Paul A. Wagner.

The one-year performance of Forte Biosciences Inc. stock is 106.87%, while year-to-date (YTD) performance is 11.45%. FBRX stock has a five-year performance of %. Its 52-week range is between 13.35 and 53.99, which gives FBRX stock a 52-week price range ratio of 67.00%

Forte Biosciences Inc. currently has a PE ratio of -4.40, a price-to-book (PB) ratio of 10.08, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -86.28%, a ROC of -90.02% and a ROE of -90.02%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Forte Biosciences Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.39 for the next earnings report. Forte Biosciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Forte Biosciences Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Forte Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Forte Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Forte Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.50, ATR14 : 2.47, CCI20 : 92.78, Chaikin Money Flow : 0.30, MACD : 1.86, Money Flow Index : 58.24, ROC : 18.72, RSI : 58.85, STOCH (14,3) : 69.11, STOCH RSI : 0.05, UO : 54.85, Williams %R : -30.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Forte Biosciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Forte Biosciences Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial.

CEO: Paul A. Wagner

Telephone: +1 310 618-6994

Address: 1124 W Carson Street, Torrance 90502, CA, US

Number of employees: 9

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits